Disease · HP_0007359
Focal-onset seizure
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Focal-onset seizure. Diseases, record HP_0007359. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0007359
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Focal-onset seizure
- Open Targets ID
- HP_0007359
- Other names
- Focal seizure, Focal seizures, Focal-onset seizures, Partial seizure, Partial seizures, Seizure affecting one half of brain
- Highest stage of its drugs
- Approval, for 1 of its 27 drugs, from PMDA
Source Open Targets
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GABAPENTIN | CHEMBL940 | Small molecule | Approval | PMDA | 3 | 2 | 2 | Drugs and targets |
| PREGABALIN | CHEMBL1059 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| LACOSAMIDE | CHEMBL58323 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| LEVETIRACETAM | CHEMBL1286 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| PERAMPANEL | CHEMBL1214124 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| LAMOTRIGINE | CHEMBL741 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| BRIVARACETAM | CHEMBL607400 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ESLICARBAZEPINE ACETATE | CHEMBL87992 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| OXCARBAZEPINE | CHEMBL1068 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| AZETUKALNER | CHEMBL5095264 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets68
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN8A | Sodium channel alpha subunit | 10 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor; Sodium channel protein type VIII alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6334 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN9A | Sodium channel alpha subunit | 9 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/6335 | Drugs and targets |
1 to 10 of 68
See all 68 targetsTrials102
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00735397 | Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures | Phase 3 | 1,218 | 2016-01-26 | Epilepsy | PERAMPANEL | Its record names the disease | ClinicalTrials.gov |
| NCT01261325 | Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures | Phase 3 | 768 | 2016-08-15 | Epilepsy | BRIVARACETAM | Its record names the disease | ClinicalTrials.gov |
| NCT00700310 | Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures | Phase 3 | 712 | 2012-11-22 | Refractory Partial Seizures | PERAMPANEL | Its record names the disease | ClinicalTrials.gov |
| NCT00280059 | Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy | Phase 3 | 660 | 2011-10-24 | Epilepsy, Partial | LAMOTRIGINE, PREGABALIN | Its record names the disease | ClinicalTrials.gov |
| NCT00988429 | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures | Phase 3 | 653 | 2014-04-15 | Partial Epilepsy | ESLICARBAZEPINE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00537238 | Pregabalin Versus Levetiracetam In Partial Seizures | Phase 3 | 509 | 2013-07-11 | Partial Seizures | LEVETIRACETAM, PREGABALIN | Its record names the disease | ClinicalTrials.gov |
| NCT01832038 | Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures | Phase 3 | 473 | 2020-08-13 | Epilepsy, Partial-onset Seizures | LACOSAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03083665 | A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy | Phase 3 | 449 | 2023-11-09 | Partial Seizures With or Without Secondary Generalization, Epilepsy | BRIVARACETAM | Its record names the disease | ClinicalTrials.gov |
| NCT01866111 | A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures | Phase 2 | 437 | 2022-04-29 | Partial Epilepsy | CENOBAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT03373383 | Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy | Phase 2 | 411 | 2021-04-09 | Drug-resistant Epilepsy, Focal-Onset Seizures | PADSEVONIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 102
See all 102 trialsComparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pregabalin vs Lamotrigine: Exit Due to Adverse Events During the Double-blind Treatment Phase (Including Dose Escalation Phase) | 33 of 330 | 31 of 330 | 660 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: Exit for Any Reason During the Double-blind Treatment Phase (Including Dose Escalation Phase) | 94 of 330 | 80 of 330 | 660 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: serious adverse events | 44 of 330 | 32 of 330 | 660 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: Exit Due to Lack of Efficacy After 4-week Dose Escalation Phase | 78 of 329 | 58 of 330 | 659 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: Exit Due to Any Reason After 4-week Dose Escalation Phase | 78 of 329 | 58 of 300 | 629 | NCT00280059 | Trial comparisons |
| Pregabalin vs Levetiracetam: serious adverse events | 24 of 254 | 24 of 255 | 509 | NCT00537238 | Trial comparisons |
| Rufinamide vs Placebo: deaths from any cause | 0 of 176 | 0 of 180 | 356 | NCT00334958 | Trial comparisons |
| Rufinamide vs Placebo: serious adverse events | 6 of 176 | 7 of 180 | 356 | NCT00334958 | Trial comparisons |
| Lacosamide vs Placebo: deaths from any cause | 0 of 171 | 0 of 172 | 343 | NCT01921205 | Trial comparisons |
| Lacosamide vs Placebo: serious adverse events | 11 of 171 | 13 of 172 | 343 | NCT01921205 | Trial comparisons |
1 to 10 of 29
See all 29 comparisons in its trialsPapers from its trials82
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0007359
GET https://conductscience.org/api/diseases/v1/HP_0007359/drugs?page=2